the torch Summer 2017, Issue 2 - Page 12

Pancreatic cancer patients seeing promising results in AGAP Trial at Baylor For many patients with inoperable pancreatic cancer, hope is fleeting. Current chemotherapy regimens and radiation therapy provide limited help against this type of aggressive cancer. The five-year survival rate for pancreatic cancer hovers around 5 percent, the lowest of all cancers. But a new clinical trial at Baylor Charles A. Sammons Cancer Center in Dallas is giving hope to a group of exacerbated by inflammation from the cancer. Inflammation is also problematic for some types of breast cancer. A different team of researchers at Baylo ȁ‘…Ω”‰••ΈΝΡΥ‘ε₯Ήœ‘½ά…Έ)…ΉΡ€΅₯Ή™±…΅΅…ѽȁ䁑Ι՜…±±•)…Ή…­₯ΉΙ„…Έ‘•±ΐ‰Ι•…ΝЁ…Ή•Θ)Α…Ρ₯•ΉΡΜΈ …Ν•½ΈΑ½Ν₯Ρ₯Ω”½Υэ½΅•Μ)½˜Ρ‘…ЁΝΡՑ䰁ɕ͕…ɍ‘•Ί±•…‘₯ΉœΡ‘”)@QΙ₯…°…Ι”…‘‘₯Ήœ…Ή…­₯ΉΙ„ΡΌ„)Ρ‘Ι•”΅‘Ι՜‘•΅½Ρ‘•Ι…Α䁍½΄΄)‰₯Ή…Ρ₯½Έ€‘Ή…ˆ΅Α…±₯Ρ…α•°°•΅₯Ρ…‰₯Ή”)…Ή₯ΝΑ±…Ρ₯Έ€ΡΌΙ•‘Ս”₯Ή™±…΅΅…Ρ₯½Έ)…ΉΝ‘Ι₯Ή¬Α…ΉΙ•…Ρ₯ŒΡΥ΅½ΙΜΈ́ё”)₯Ή™±…΅΅…Ρ₯½Έ½•Μ‘½έΈ°Α…Ρ₯•ΉΡΜ)…Ι”Ι•Α½ΙΡ₯ΉœΡ‘…Ёё•δ™••°‰•ΡΡ•ΘΈ)Q‘•Ι—Šé‰••ΈΝΌ΅Υ •ΉΡ‘ΥΝ₯…Ν΄)Α…ΉΙ•…Ρ₯Œ…Ή•ΘΑ…Ρ₯•ΉΡΜΈQ‘Ύ™…Θ°…Ι½ΥΉΡ‘”ΡΙ₯…°Ρ‘…Π°…™Ρ•Θ±…ΥΉ‘₯Ήœ)…Ё …屽ȁ‘…Ω”Ν••ΈΡ‘•₯ȁΡΥ΅½Ίё•₯ȁ•ΉΙ½±±΅•ΉΠ½…°½˜€Δ؁Α…Ρ₯•ΉΡΜ)…±°Α…Ρ₯•ΉΡ́•ΉΙ½±±•₯ΈΡ‘”@QΙ₯…°)Ν‘Ι₯Ή¬™Ι½΄…Έ₯Ή½Α•Ι…‰±”ΝΡ…Ρ”ΡΌ…Έ)½Α•Ι…‰±”½Ή”Έ)½Ι‘₯ΉœΡΌ …Ι±½Μ ••ΙΙ„°)4ΉΈ°Ρ‘”ΑΙ₯Ή₯Α…°₯ΉΩ•ΝΡ₯…ѽȁ™½Θ)Ρ‘”ΝΡՑ䰁½Ή”½˜Ρ‘”΅½ΝЁ₯ΉΡ•Ι•ΝΡ₯Ήœ)₯Έ)…ΉΥ…Ιδ€ΘΐΔΨ°Ι•Ν•…ɍ‘•Ίɕ…‘•)‰δΡ‘”ε•…ΛŠé•ΉΈQ‘•δ…±ΝΌΙ••ΉΡ±δ)Ι••₯Ω•…ΑΑΙ½Ω…°ΡΌ₯ΉΙ•…Ν”Ρ‘”)ΉΥ΅‰•Θ½˜Α…ΙΡ₯₯Α…Ρ₯ΉœΑ…Ρ₯•ΉΡΜ)Q‘”₯ΉΙ•…Ν”έ₯±°•Ή‘…Ή”Ρ‘”)ΝΡΥ‘ηŠéΝΡ…Ρ₯ΝΡ₯…°Α½έ•ΘΈQ‘₯́έ₯±°°₯Έ)Α…Ρ‘½±½δΑ½ΝΠ΅ΝΥɝ•Ι䰁΅•…Ή₯ΉœΉΌ₯΅ΑΙ½Ω”‘…Ή•Μ½˜Ν•ΥΙ₯Ήœ)…Ή•Θ•±±Μέ•Ι”™½ΥΉ…Ёё”½ΥΡ•Θ)•‘”½˜Ρ‘”Ρ₯ΝΝΥ”Ρ‘…Ё݅́ɕ΅½Ω•Έ)Q‘”Ι•Ν•…ɍ Ρ•…΄έ₯±°½ΉΡ₯ΉΥ”ΡΌ)ΡΥΙΈ°ΑΙ½Ω₯‘”Ι½‰ΥΝЁ‘…Ρ„Ρ‘…Ёέ₯±°)…‘‘₯Ρ₯½Ή…°™ΥΉ‘₯Ήœ™½Θ„±…ɝ•ΘΝΡΥ‘δ)…™Ρ•ΘΡ‘₯́₯Ή₯Ρ₯…°ΡΙ₯…°₯́½΅Α±•Ρ”Έ+ŠqQ‘₯́ΡΙ₯…°‘…́₯ΉΩ₯½Ι…Ρ•Ρ‘”)΅•…ΝΥΙ”‘₯Ν•…Ν”΅™Ι•”ΝΥΙΩ₯Ω…°₯ΈΑ…ΉΙ•…́ѕ…΄‘•Ι”…Ё …ε±½Θ³ŠtΝ…₯)QΌΝ‘Ι₯Ή¬Α…ΉΙ•…Ρ₯ŒΡΥ΅½ΊѼ…ΈΑΙ₯Ή₯Α…°₯ΉΩ•ΝΡ₯…ѽȁ™½ΘΡ‘₯́ΝΡΥ‘δΈ)Ρ‘•Ν”Α…Ρ₯•ΉΡΜΈ)½Α•Ι…‰±”ΝΡ…Ρ”°‘•΅½Ρ‘•Ι…Αδ)ΡΙ•…Ρ΅•ΉΡ́‘…Ω”ΡΌ‘₯Ёё•₯ȁхɝ•ΠΈ) ΥЁё₯́₯́‘₯™™₯Υ±Πέ₯Ρ Α…ΉΙ•…Ρ₯Œ)ΡΥ΅½Ί‰•…ΥΝ”Ρ‘•ηŠeΙ”½™Ρ•Έ)‰±½­•‰δ‘•ΉΝ”½ΉΉ•Ρ₯Ω”Ρ₯ΝΝΥ”)ΘΈM½ΡЁ •±₯ΉΝ­€)ΡΌ€ΘΐΈ)™₯Ή‘₯ΉΜ₯́ё…Ё…±°½˜Ρ‘•Ν”Α…Ρ₯•ΉΡΜ)‘…Ω”‘…Ή•…Ρ₯Ω”΅…ɝ₯ΉΜ½Έ)ΘΈ …Ι±½Μ ••ΙΙ„)M½ΡЁ •±₯ΉΝ­€°4ΉΈ°…Ή½Ρ‘•Θ+Šq]”‘…Ω”‰••Έ…‰±”ΡΌ•Ή½ΥΙ…”)Α‘εΝ₯₯…ΉΜΡΌΙ•½΅΅•ΉΑ…Ρ₯•ΉΡΜ)™½ΘΡ‘•Ν”±₯Ή₯…°ΡΙ₯…±ΜΈ]”­Ή½άΡ‘…Π)Ρ‘”Ή••‘±”έ½»ŠeЁ΅½Ω”έ₯Ρ‘½ΥΠ)Α…ΙΡ₯₯Α…Ρ₯½ΈΈQ‘”•ΉΡ‘ΥΝ₯…Ν΄₯Μ(ΔΘ+ŠqQ‘₯́ΡΙ₯…°‘…́₯ΉΩ₯½Ι…Ρ•)Ρ‘”Α…ΉΙ•…́ѕ…΄‘•Ι”)…Ё …ε±½Θ»Št($+ŠPΘΈM½ΡЁ •±₯ΉΝ­€